
Certara, Inc. — Investor Relations & Filings
Certara, Inc. is a company that accelerates drug discovery and development through the use of proprietary biosimulation software, technology, and expert services. It provides an end-to-end platform that supports clients across the entire drug development lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's solutions leverage predictive simulation, data-driven modeling, and advanced analytics to help pharmaceutical and biotechnology organizations optimize trial design, justify dosing decisions, and navigate regulatory requirements. Key software products include Simcyp, Phoenix, and Pinnacle 21. Certara's offerings are designed to de-risk development, enhance efficiency, and increase the likelihood of bringing new medicines to patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | |
| ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | |
| 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | |
| 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 35223149 | 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | ||
| 33256151 | ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 33255090 | DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 32899219 | 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | ||
| 32899221 | 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 32899220 | 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 13319431 | Director's Dealing 2026 | 2026-01-12 | English | ||
|
2025
8 filings
| |||||
| 13319432 | FORM 8-K | 2025-12-11 | English | ||
| 13319433 | Major Shareholding Notification 2025 | 2025-11-25 | English | ||
| 13319434 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13319435 | Director's Dealing 2025 | 2025-11-12 | English | ||
| 13319436 | 10-Q | 2025-11-06 | English | ||
| 13319437 | 8-K | 2025-11-06 | English | ||
| 13319438 | FORM 8-K | 2025-10-16 | English | ||
| 13319439 | Major Shareholding Notification 2025 | 2025-10-09 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NANOVIRICIDES, INC.
Clinical-stage biopharma developing broad-spectrum, nanomed…
|
NNVC | US | Professional, scientific and te… |
|
Natcore Technology Inc.
R&D entity using nanotechnology to improve solar cell effic…
|
NTCXF | CA | Professional, scientific and te… |
|
Nautilus Biotechnology, Inc.
Develops a proteome analysis platform to quantify proteins …
|
NAUT | US | Professional, scientific and te… |
|
NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno…
|
950220 | US | Professional, scientific and te… |
|
Neovacs
Biotech firm developing immunotherapies and investing in Bi…
|
ALNEV | FR | Professional, scientific and te… |
|
NervGen Pharma Corp.
Clinical-stage biotech developing treatments to promote ner…
|
NGEN | CA | Professional, scientific and te… |
|
NEUREN PHARMACEUTICALS LIMITED
Develops innovative therapies for rare neurodevelopmental d…
|
NEU | NZ | Professional, scientific and te… |
|
NEURIZON THERAPEUTICS LIMITED
Clinical-stage developer of mTOR modulators for ALS and neu…
|
NUZ | AU | Professional, scientific and te… |
|
NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD
Develops peptide-based therapeutics for neurodegenerative a…
|
NSB | AU | Professional, scientific and te… |
|
NEUROTECH INTERNATIONAL LIMITED
Clinical-stage biopharmaceutical company developing pediatr…
|
NTI | AU | Professional, scientific and te… |
Certara, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31699/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31699 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31699 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31699 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31699}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Certara, Inc. (id: 31699)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.